Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-07-03Clinical Trial Update: A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma [Phase 1]
Phase 1 study evaluating escalating doses of RO7297089 to assess safety and pharmacokinetics in patients with relapsed or refractory multipl…
-
CLINICAL_TRIALS trial_result · 2024-07-03Clinical Trial Update: Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma
A Travera Inc.-sponsored study evaluated Mass Accumulation Rate as a predictive biomarker in relapsed multiple myeloma; the trial has been t…
-
CLINICAL_TRIALS trial_result · 2024-07-03Clinical Trial Update: TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 3]
Phase 3 trial TJ202 evaluating lenalidomide plus dexamethasone versus lenalidomide plus dexamethasone in relapsed or refractory multiple mye…
-
CLINICAL_TRIALS trial_result · 2024-07-01Clinical Trial Update: Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure [Phase 2]
A Phase 2 trial of a daratumumab-based regimen for newly diagnosed multiple myeloma with kidney failure has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-07-01Clinical Trial Update: Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma [Phase 1]
Phase 1 trial evaluating autologous CD8+ T cells engineered to express an anti-BCMA CAR for multiple myeloma has been terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-06-28Clinical Trial Update: A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects [Phase 1]
Phase 1 study comparing pharmacokinetics, safety, tolerability, and immunogenicity of HLX15 versus daratumumab in male subjects with multipl…
-
CLINICAL_TRIALS trial_result · 2024-06-28Clinical Trial Update: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
The clinical trial update reports safety and efficacy findings for ALLO-605, an anti-BCMA allogeneic CAR T-cell therapy, in relapsed/refract…
-
CLINICAL_TRIALS trial_result · 2024-06-28Clinical Trial Update: LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma [NA]
A clinical trial update for LCAR-M61S and LCAR-M61D in Relapsed/Refractory Multiple Myeloma; the study is currently not recruiting.
-
CLINICAL_TRIALS trial_result · 2024-06-27Clinical Trial Update: Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients [Phase 2]
Phase 2 study evaluating somatostatin receptor imaging in relapsing and refractory multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2024-06-18Clinical Trial Update: Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) [Phase 2]
Phase 2 MATCH subprotocol evaluating AZD9291 (osimertinib) as a targeted treatment for cancers with EGFR genetic changes; the trial is curre…
-
CLINICAL_TRIALS trial_result · 2024-06-18Clinical Trial Update: Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) [Phase 2]
Phase 2 trial evaluating Erdafitinib (JNJ-42756493) for cancers with FGFR amplifications; the study includes advanced and refractory lymphom…
-
CLINICAL_TRIALS trial_result · 2024-06-18Clinical Trial Update: QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
The QUILT-3.020 trial evaluating ALT-801 in relapsed or refractory multiple myeloma has been terminated, with results posted on 2024-06-18.
-
CLINICAL_TRIALS trial_result · 2024-06-14Clinical Trial Update: Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients [Phase 1, Phase 2]
This clinical trial update reports results from a Phase 1/2 study of isatuximab in combination with cemiplimab in relapsed/refractory multip…
-
CLINICAL_TRIALS trial_result · 2024-06-13Clinical Trial Update: Prevention of Treatment Induced Neuropathy in Multiple Myeloma [Phase 2]
Phase 2 clinical trial update on preventing treatment-induced neuropathy in multiple myeloma; the study has completed and results were poste…
-
CLINICAL_TRIALS trial_result · 2024-06-13Clinical Trial Update: Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib [Phase 2]
A phase 2 trial evaluating ixazomib citrate in patients with relapsed multiple myeloma that is not refractory to bortezomib has completed an…
-
CLINICAL_TRIALS trial_result · 2024-06-13Clinical Trial Update: Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma [Phase 1]
This clinical trial update notes the completion of a Phase 1 study of ISB 1342, a CD38/CD3 bispecific antibody, in subjects with relapsed/re…
-
CLINICAL_TRIALS trial_result · 2024-06-11Clinical Trial Update: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies [Phase 1]
Phase 1 study of STRO-001, an anti-CD74 antibody-drug conjugate, in advanced B-cell malignancies has been completed.
-
CLINICAL_TRIALS trial_result · 2024-06-06Clinical Trial Update: Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma [Phase 1]
Phase 1 trial evaluating panobinostat in combination with daratumumab, bortezomib, and dexamethasone for relapsed/refractory multiple myelom…
-
CLINICAL_TRIALS trial_result · 2024-05-29Clinical Trial Update: A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]
Phase 3 trial comparing Daratumumab, Bortezomib, and Dexamethasone (DVd) versus Bortezomib and Dexamethasone (Vd) in Chinese participants wi…
-
CLINICAL_TRIALS trial_result · 2024-05-28Clinical Trial Update: Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer [Phase 1]
Phase 1 clinical trial evaluating the combination of sodium selenite with radiation therapy in patients with metastatic cancer.
-
CLINICAL_TRIALS trial_result · 2024-05-24Clinical Trial Update: Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma [Phase 1, Phase 2]
This update reports the completion and posted results of a Phase 1/2 trial evaluating the safety and efficacy of the CAR-T therapy JCARH125 …
-
CLINICAL_TRIALS trial_result · 2024-05-24Clinical Trial Update: Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma [Phase 1]
This update reports the completion of a Phase 1 study evaluating vactosertib in combination with pomalidomide for relapsed or relapsed/refra…
-
CLINICAL_TRIALS trial_result · 2024-05-24Clinical Trial Update: Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy [NA]
A completed clinical trial evaluating the feasibility of a digital health coaching program for individuals after CAR T-cell therapy.
-
CLINICAL_TRIALS trial_result · 2024-05-23Clinical Trial Update: Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation [Phase 4]
Phase 4 clinical trial evaluating the safety and efficacy of high-dose melphalan hydrochloride for injection in multiple myeloma patients un…
-
CLINICAL_TRIALS trial_result · 2024-05-22Clinical Trial Update: Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide [Phase 2]
A Phase 2 trial evaluating nivolumab in combination with daratumumab, with or without low-dose cyclophosphamide, for multiple myeloma has co…